Plain-English translation of NCT06044675 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether MDMA, combined with a type of couples therapy called cognitive-behavioral conjoint therapy (CBCT), helps reduce PTSD symptoms better than CBCT alone. The study involves both the person with PTSD and a close loved one (like a partner or family member). Researchers believe that MDMA may help people feel more open, trusting, and able to process difficult emotions during therapy sessions.
PTSD often damages relationships and makes it hard for people to heal, and current treatments don't work for everyone. Researchers want to see if this medication can enhance the therapy process by helping people stay engaged and feel safer processing traumatic memories, while also improving how couples communicate and support each other.
You likely qualify if…
You likely don't qualify if…
You and your loved one would attend a 7-week course of couples therapy together. If randomly assigned to the medication group, you would participate in two full-day sessions where you receive the medication alongside your therapy; if assigned to therapy-only, you receive standard couples therapy. Either way, you attend regular therapy visits, stay overnight after medication sessions (if applicable), and allow sessions to be recorded. The study requires commitment to all appointments and following study rules.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Canada